-
Jan 23, 2025 | 
radcliffecvrm.com | Faiez Zannad |Anish Gupta |Stephen Greene |Michelle M. Kittleson
Although cardio-kidney-metabolic disease (CKMD) incorporates conditions which share common risk factors, guidelines are often complex and vary between specialist groups. How can we achieve simpler CKMD guidelines to improve implementation? In this short interview, Dr Faiez Zannad (University of Lorraine, Nancy, FR) advocates for a single-set of overarching CKMD guidelines across all specialties.
-
Dec 1, 2024 | 
jacc.org | Wolfram Doehner |Stefan Anker |Javed Butler |Faiez Zannad
References1. "Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial)". Am J Cardiol . 2014;114:1713-1721. 2. "Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging". Circulation . 2003;107:1991-1997. 3.
-
Nov 23, 2024 | 
onlinelibrary.wiley.com | Mika Hilvo |Faiez Zannad |Angelika Witoslawska |Antti Jylhä
1 INTRODUCTION Heart failure (HF) is a clinical syndrome resulting from a cardiac disorder that can be associated with many cardiovascular (CV) diseases, such as coronary artery disease (CAD).1 HF is becoming a major health crisis with over 60 million people affected globally.2 With an increasing global prevalence of HF, the number of HF-related hospitalisations is also rising and any subsequent hospitalization increases the mortality risk of patients with HF.3 Ceramides (Cer) are a class of...
-
Oct 28, 2024 | 
nature.com | Pardeep S. Jhund |Meike Brinker |Peter Kolkhof |Michele Senni |Sanjiv Shah |Adriaan A. Voors | +3 more
Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03264-4, published online 1 September 2024. In the version of the article initially published, the first three columns of the “New-onset atrial fibrillation” row of Fig. 1 originally read “286 (3.0)”, “1.3”, “345 (3.6)” and have now been amended to “286 (3.9)”, “1.4”, “345 (4.7)” in the HTML and PDF versions of the article.
-
Oct 14, 2024 | 
nature.com | Faiez Zannad |C. Michael Gibson |Cecilia Linde |Thomas F. Luscher |Thomas F. Lüscher |Richard Mindham | +3 more
AbstractCardiovascular clinical trials continue to under-represent children, older adults, females and people from ethnic minority groups relative to population disease distribution. Here we describe strategies to foster trial representativeness, with proposed actions at the levels of trial funding, design, conduct and dissemination.
-
Sep 5, 2024 | 
nature.com | Fang-Fei Wei |Pierpaolo Pellicori |Joao Ferreira |Arantxa González |De-Wei An |Chen Liu | +10 more
AbstractNone of the spironolactone trials in heart failure (HF) assessed the blood pressure (BP) responses to exercise, while conflicting results were reported for exercise capacity. In the HOMAGE trial, 527 patients at increased HF risk were randomized to usual treatment with or without spironolactone (25–50 mg/day). The current substudy included 113 controls and 114 patients assigned spironolactone, who all completed the incremental shuttle walk test at baseline and months 1 and 9.
-
Sep 3, 2024 | 
nature.com | Faiez Zannad |Arun J Sanyal |Veronica Miller
AbstractThe intersection of cardiovascular disease, metabolic disorders and chronic kidney disease represents a complex clinical picture challenging healthcare systems worldwide. Metabolic-dysfunction-associated steatotic liver disease (MASLD) often manifests sequentially or concomitantly with these diseases, and may share underlying mechanisms and risk factors.
-
Sep 1, 2024 | 
nature.com | Pardeep S. Jhund |Meike Brinker |Peter Kolkhof |Michele Senni |Sanjiv Shah |Adriaan A. Voors | +3 more
AbstractCardiovascular-kidney-metabolic syndrome is an emerging entity that connects cardiovascular diseases, chronic kidney disease, and diabetes. The non-steroidal mineralocorticoid receptor antagonist, finerenone, has been studied in three prospective randomized clinical trials of patients with cardio-kidney-metabolic syndrome: FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF.
-
Jun 6, 2024 | 
academic.oup.com | Carmine Zoccali |Faiez Zannad
Are you interested in your research being part of a collection like this? Learn more about ERA and ESC journal resources for prospective authors:Cardiovascular and kidney diseases are intricately linked, with their coexistence significantly increasing the risk of adverse outcomes and mortality.
-
May 13, 2024 | 
onlinelibrary.wiley.com | Faiez Zannad |Université de Lorraine |Arun J Sanyal |Javed Butler
AST aspartate aminotransferase/aspartate transaminase CKD chronic kidney disease DALY disability-adjusted life year FIB4 Fibrosis-4 index GBD Global Burden of Disease GIP glucose-dependent insulinotropic peptide GLP-1 RA glucagon-like peptide 1 receptor agonist MACE major adverse CV event MASH metabolic dysfunction-associated steatohepatitis MASLD metabolic dysfunction-associated steatotic liver disease MOSAIC Metabolic multi Organ Science Accelerating Innovation in Clinical Trials MRA...
